In summary, we show that critical aspects of cancer cell function are dependent on the presence of IdoA in DS, and specific features of the CS/DS structure are altered in ESCC patient tumors. This work demonstrates the potential to pharmalogically block DS-epi1 and expectably down-regulate HGF signaling, which may provide new avenues for cancer treatment.
